Mesothelioma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Cancer;   Breast Cancer;   Gastric Cancer;   Non Small Cell Lung Cancer;   Cervical Cancer;   Endocervical Cancer;   Squamous Cell Carcinoma of Head and Neck;   Bladder Urothelial Cancer;   Colorectal Cancer;   Esophageal Cancer;   Ovarian Cancer;   Rena l Cell Carcinoma;   Prostate Cancer;   Melanoma;   Mesothelioma;   Cholangiocarcinoma Interventions:   Drug: NGM438;   Drug: NGM438 plus pembrolizumab Sponsor:   NGM Biopharmaceuticals, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2022 Category: Research Source Type: clinical trials

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Conditions:   Malignant Pleural Mesothelioma;   Unresectable Malignant Neoplasm Intervention:   Other: Data collection Sponsors:   Groupe Francais De Pneumo-Cancerologie;   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2022 Category: Research Source Type: clinical trials